Seattle Genetics sets Adcetris price

Seattle Genetics Inc. (NASDAQ:SGEN) set the wholesale acquisition cost of lymphoma drug Adcetris brentuximab vedotin at $13,500 per dose. A full course of treatment for the drug would cost about $94,500-$121,500, based on a median treatment duration of seven to nine doses observed in clinical trials. The biotech launched Adcetris Monday. FDA approved the drug Friday.

Adcetris is indicated for Hodgkin's lymphoma patients who have progressed after autologous stem cell transplant (ASCT) or after two prior chemotherapies and are transplant ineligible. There are no FDA approved agents for these patients, who receive a mix of single-agent chemotherapies as salvage treatment. Adcetris is also indicated for relapsed anaplastic large cell lymphoma, which is treated with several multi-agent chemotherapies including EPOCH, ESHAP, ICE. ...